Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Moodys
Farmers Insurance
Argus Health
US Department of Justice
Deloitte
QuintilesIMS
Merck
Cantor Fitzgerald

Generated: January 19, 2019

DrugPatentWatch Database Preview

OVIDREL Drug Profile

« Back to Dashboard

When do Ovidrel patents expire, and what generic alternatives are available?

Ovidrel is a drug marketed by Emd Serono and is included in one NDA. There is one patent protecting this drug.

This drug has eighteen patent family members in fourteen countries.

The generic ingredient in OVIDREL is choriogonadotropin alfa. One supplier is listed for this compound. Additional details are available on the choriogonadotropin alfa profile page.

Summary for OVIDREL
International Patents:18
US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 25
Drug Prices: Drug price information for OVIDREL
DailyMed Link:OVIDREL at DailyMed
Drug patent expirations by year for OVIDREL
Generic Entry Opportunity Date for OVIDREL
Generic Entry Date for OVIDREL*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;SUBCUTANEOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for OVIDREL
Drug ClassGonadotropin

US Patents and Regulatory Information for OVIDREL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Emd Serono OVIDREL choriogonadotropin alfa INJECTABLE;INJECTION 021149-001 Sep 20, 2000 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Emd Serono OVIDREL choriogonadotropin alfa INJECTABLE;SUBCUTANEOUS 021149-002 Oct 6, 2003 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for OVIDREL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Emd Serono OVIDREL choriogonadotropin alfa INJECTABLE;INJECTION 021149-001 Sep 20, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Emd Serono OVIDREL choriogonadotropin alfa INJECTABLE;SUBCUTANEOUS 021149-002 Oct 6, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for OVIDREL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB01/030 United Kingdom ➤ Try a Free Trial PRODUCT NAME: RECOMBINANT CHORIOGONADOTROPIN ALFA; REGISTERED: UK EU/1/00/165/001-006 20010202
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Federal Trade Commission
Argus Health
Merck
Covington
McKinsey
McKesson
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.